http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2016201691-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7de02e4b28736bfb52de8bb358be203e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 |
| filingDate | 2016-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cfa68536baf19d117afcdd80f795be6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f11f885e596cc0f82baef5d753a47ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c97d40d956d98f4c1d50dbfcf717960 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75f7706e617beec7d1a882fff9c5b77d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57908ebe449f20fa8ad6a7516285f588 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2c7f5530a34a855a15c036bf82a3284 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5133b46d3ad87e3a7f0a042546714f2d |
| publicationDate | 2016-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2016201691-A1 |
| titleOfInvention | Vaccine compositions and methods of use thereof |
| abstract | Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle-based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110448695-A |
| priorityDate | 2009-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 231.